Strong evidence of benefit:* |
Moderate-to-severe allergic asthma (patients greater than 6 years of age) |
Chronic spontaneous urticaria (patients greater than 12 years of age) |
Chronic rhinosinusitis with nasal polyposis (patients greater than 18 years of age) |
IgE-mediated food allergy, for protection from systemic allergic reactions, in conjunction with food allergen avoidance (patients ≥1 year of age ) |
Good evidence of benefit: |
Chronic inducible urticaria |
Allergic rhinitis |
Protection from systemic allergic reactions during aeroallergen, venom, or food immunotherapy |
Protection from systemic allergic reactions during drug desensitization |
Viral-induced asthma exacerbations |
Some evidence of benefit: |
Nonallergic asthma |
Mast cell activation disorders |
Atopic dermatitis |